Abstract
OBJECTIVE: The aim of this study was to assess the influence of patient body weight on the clinical effect of 100 mg diclofenac administered as a single dose for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).
MATERIALS AND METHODS: All patients subjected to endoscopic retrograde cholangiopancreatography (ERCP) from 2009 to 2014 were evaluated for inclusion. In total, 772 patients were included of whom 378 (49%) received diclofenac prophylaxis.
RESULTS: In the diclofenac prophylaxis group, body weight was higher in patients with PEP (mean ± SD: 82 ± 18 kg) than in patients without PEP (74 ± 18 kg) (p = 0.029). In patients not receiving prophylaxis, body weight was not associated with the occurrence of PEP (mean ± SD: 77 ± 18 vs 75 ± 18 kg, respectively, p = 0.450). In an adjusted analysis, higher patient body weight was inversely associated with the clinical effect of 100 mg diclofenac for the prophylaxis of PEP.
CONCLUSIONS: High patient body weight was associated with a reduced effect of 100 mg diclofenac for prophylaxis of PEP.
| Original language | English |
|---|---|
| Book series | Scandinavian Journal of Gastroenterology |
| Volume | 51 |
| Issue number | 8 |
| Pages (from-to) | 1007-12 |
| Number of pages | 6 |
| ISSN | 0036-5521 |
| DOIs | |
| Publication status | Published - 2 Aug 2016 |
Keywords
- Acute Disease
- Aged
- Body Weight
- Cholangiopancreatography, Endoscopic Retrograde
- Diclofenac
- Female
- Humans
- Logistic Models
- Male
- Pancreatitis
- Journal Article